Sarah E. S. Leary
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sarah E. S. Leary has a total of 809 co-authors. Here are the top co-authors by number of shared publications:
- Bonnie L. Cole
Seattle Department of Laboratories, Seattle Children's Hospital, Seattle, WA
17 shared publications - Erin E. Crotty
Ben Towne Center for Childhood Cancer and Blood Disorders Research, Seattle Children’s Research Institute , Seattle, Washington
13 shared publications - Nicholas A. Vitanza
Ben Towne Center for Childhood Cancer and Blood Disorders Research, Seattle Children’s Research Institute, Seattle, USA
12 shared publications Amy Lee
Seattle Children's
11 shared publications- Jeffrey G. Ojemann
Department of Neurological Surgery, University of Washington, Seattle, WA, USA
11 shared publications - Juliane Gust
Norcliffe Foundation Center for Integrative Brain Research, Seattle Children’s Research Institute , Seattle, Washington
10 shared publications
Latest Publications
- 11 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
SPROUT Guidelines for Molecular Profiling for Children with Solid Tumors: A Consensus Recommendation from the American Association for Cancer Research
Purpose: Molecular diagnostics are standard of care for most adults with solid malignancies, but implementation in pediatric solid tumors remains inconsistent. The SPROUT (Somatic Profiling for Pediatric Cancer Refining our Understanding and Treatment) Molecular Guidelines Working Group was convened to develop molecular testing guidelines for pediatric solid tumors. Experimental Design: A structured literature review was performed using Covidence to identify relevant clinical studies evaluating molecular diagnostics in pediatric solid tumors. The literature and collective clinical experience of the multidisciplinary working group were used to develop consensus recommendations for molecular profiling at diagnosis and at relapse or recurrence. Results: Of 361 manuscripts screened, 41 studies were included for data extraction. Based on the available evidence and expert consensus, recommendations were developed for the use and timing of DNA and RNA next-generation sequencing and methylation profiling across pediatric solid tumors. Conclusions: The SPROUT Molecular Guidelines provide a framework for standardized implementation of molecular diagnostics in pediatric solid tumors. Broad adoption of these recommendations may improve diagnostic precision, reduce variability in molecular testing, and increase opportunities for biomarker-directed therapy and clinical trial enrollment for children with cancer.
- 11 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
SPROUT Guidelines for Molecular Profiling for Children with Solid Tumors: A Consensus Recommendation from the American Association for Cancer Research
Purpose: Molecular diagnostics are standard of care for most adults with solid malignancies, but implementation in pediatric solid tumors remains inconsistent. The SPROUT (Somatic Profiling for Pediatric Cancer Refining our Understanding and Treatment) Molecular Guidelines Working Group was convened to develop molecular testing guidelines for pediatric solid tumors. Experimental Design: A structured literature review was performed using Covidence to identify relevant clinical studies evaluating molecular diagnostics in pediatric solid tumors. The literature and collective clinical experience of the multidisciplinary working group were used to develop consensus recommendations for molecular profiling at diagnosis and at relapse or recurrence. Results: Of 361 manuscripts screened, 41 studies were included for data extraction. Based on the available evidence and expert consensus, recommendations were developed for the use and timing of DNA and RNA next-generation sequencing and methylation profiling across pediatric solid tumors. Conclusions: The SPROUT Molecular Guidelines provide a framework for standardized implementation of molecular diagnostics in pediatric solid tumors. Broad adoption of these recommendations may improve diagnostic precision, reduce variability in molecular testing, and increase opportunities for biomarker-directed therapy and clinical trial enrollment for children with cancer.
- Open Access
- 27 October 2026
- Published by Springer Nature in Research Square
First-in-human quad-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial
Diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG) are lethal pediatric central nervous system (CNS) tumors with a median survival of 11 months. Despite advancements in translating chimeric antigen receptor (CAR) T cells for these patients, efficacy may be constrained by antigen heterogeneity and immune escape. We conducted a first-in-human, phase 1 trial (BrainChild-04; NCT05768880) evaluating repetitive intracerebroventricular (ICV) administration of a multi-antigen targeting CAR T cell product directed against B7-H3, EGFR806, HER2 and IL13Rα2 (quad-CAR T cells) for children and young adults with DIPG/pontine DMG (Arm A) and recurrent or refractory CNS tumors (Arm B). Here we report results from Arm A. Primary endpoints were feasibility, safety, and determination of the maximally tolerated dose regimen (MTDR). Secondary endpoints included CAR T cell distribution and preliminary clinical activity. Correlative analyses assessed CAR T cell kinetics and cytokine dynamics in cerebrospinal fluid (CSF). Twenty-six patients were enrolled with 100% manufacturing success rate. Twenty-one patients received at least one infusion (median 8/patient, range 3-56). No dose-limiting toxicities occurred in the dose-finding period, and treatment was tolerable with predominantly grade 1-2 adverse events, including fever (95%), headache (86%), and fatigue (81%). One dose-limiting toxicity (acoustic nerve disorder) occurred outside the evaluation window. Repetitive ICV dosing was feasible, and most of the infused patients (86%) initiated two or more treatment courses (median 4). CAR T cells were detected in CSF in 100% of patients, across serial courses in 76% of patients, with evidence of detection across sequential courses, particularly at higher dose levels. Cytokine profiling demonstrated dynamic immune activation within the CNS. Median survival from initial CAR T infusion was 8.6 months (95% CI: 5.2-10.3). All deaths were due to disease progression. Repetitive ICV administration of quad-CAR T cells is feasible and tolerable in children and young adults with DIPG/DMG. This study represents the first clinical application of quad-antigen targeting CAR T cells and confirmed feasibility in manufacturing and preliminary evidence of biologic activity in the CNS. These findings support further evaluation of multi-antigen CAR T strategies to address tumor heterogeneity of antigen expression as a likely barrier to CAR T cell efficacy in patients with CNS tumors.
- 27 October 2026
- Published by Springer Nature in Research Square
Open AccessFirst-in-human quad-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial
Diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG) are lethal pediatric central nervous system (CNS) tumors with a median survival of 11 months. Despite advancements in translating chimeric antigen receptor (CAR) T cells for these patients, efficacy may be constrained by antigen heterogeneity and immune escape. We conducted a first-in-human, phase 1 trial (BrainChild-04; NCT05768880) evaluating repetitive intracerebroventricular (ICV) administration of a multi-antigen targeting CAR T cell product directed against B7-H3, EGFR806, HER2 and IL13Rα2 (quad-CAR T cells) for children and young adults with DIPG/pontine DMG (Arm A) and recurrent or refractory CNS tumors (Arm B). Here we report results from Arm A. Primary endpoints were feasibility, safety, and determination of the maximally tolerated dose regimen (MTDR). Secondary endpoints included CAR T cell distribution and preliminary clinical activity. Correlative analyses assessed CAR T cell kinetics and cytokine dynamics in cerebrospinal fluid (CSF). Twenty-six patients were enrolled with 100% manufacturing success rate. Twenty-one patients received at least one infusion (median 8/patient, range 3-56). No dose-limiting toxicities occurred in the dose-finding period, and treatment was tolerable with predominantly grade 1-2 adverse events, including fever (95%), headache (86%), and fatigue (81%). One dose-limiting toxicity (acoustic nerve disorder) occurred outside the evaluation window. Repetitive ICV dosing was feasible, and most of the infused patients (86%) initiated two or more treatment courses (median 4). CAR T cells were detected in CSF in 100% of patients, across serial courses in 76% of patients, with evidence of detection across sequential courses, particularly at higher dose levels. Cytokine profiling demonstrated dynamic immune activation within the CNS. Median survival from initial CAR T infusion was 8.6 months (95% CI: 5.2-10.3). All deaths were due to disease progression. Repetitive ICV administration of quad-CAR T cells is feasible and tolerable in children and young adults with DIPG/DMG. This study represents the first clinical application of quad-antigen targeting CAR T cells and confirmed feasibility in manufacturing and preliminary evidence of biologic activity in the CNS. These findings support further evaluation of multi-antigen CAR T strategies to address tumor heterogeneity of antigen expression as a likely barrier to CAR T cell efficacy in patients with CNS tumors.
- Open Access
- 1 September 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (9)
Efficacy Study of Vemurafenib in Children With Recurrent or Progressive BRAF V600E - or BRAF InsT -Mutant Brain Tumors: PNOC002
Purpose: Pediatric gliomas constitute the most prevalent central nervous system tumors in children, and aberrations in BRAF signaling contribute to their pathogenesis by disrupting the MAPK pathway. Targeted inhibition of this pathway using agents such as vemurafenib may hold therapeutic promise. Patients and Methods: PNOC002 was a multicenter trial conducted through the Pediatric Neuro-Oncology Consortium in patients younger than 25 years with recurrent or progressive BRAF V600E -mutant brain tumors. This combined phase 0/1 study aimed to establish the recommended phase II dose (RP2D) and assess preliminary efficacy, including tumor growth trajectories and rebound (defined as ≥25% increase in lesion size within 6 months, usually within 3 months, of stopping therapy). Results: Thirty-patients (range, 3-23 years) were treated at the RP2D of 550 mg/m 2 twice a day: 22 low-grade glioma (LGG) and 8 high-grade glioma (HGG). PFS at 6 months (PFS6) for the entire cohort was 80% (95% CI, 67 to 96). In patients with LGG, PFS6 was higher at 86% (95% CI, 73 to 100), compared with 63% (95% CI, 37 to 100) in patients with HGG. The best responses were stable disease (13 patients) and partial responses (13 patients). Four patients experienced PD, with three patients in the HGG cohort. Responsiveness varied by lesion type, with cystic lesions showing a larger and longer-lasting decrease in tumor size than solid lesions. Of 13 patients with LGG who discontinued treatment and had follow-up imaging, 3 (23%) experienced rebound within 78-97 days. The most common grade 3 adverse event was maculopapular rash (57%). Conclusion: Vemurafenib showed efficacy in children with recurrent or progressive BRAF V600E -mutant brain tumors with acceptable toxicity. However, the rebound rate of 23% warrants further investigation.
- 1 September 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (9)
Open AccessEfficacy Study of Vemurafenib in Children With Recurrent or Progressive BRAF V600E - or BRAF InsT -Mutant Brain Tumors: PNOC002
Purpose: Pediatric gliomas constitute the most prevalent central nervous system tumors in children, and aberrations in BRAF signaling contribute to their pathogenesis by disrupting the MAPK pathway. Targeted inhibition of this pathway using agents such as vemurafenib may hold therapeutic promise. Patients and Methods: PNOC002 was a multicenter trial conducted through the Pediatric Neuro-Oncology Consortium in patients younger than 25 years with recurrent or progressive BRAF V600E -mutant brain tumors. This combined phase 0/1 study aimed to establish the recommended phase II dose (RP2D) and assess preliminary efficacy, including tumor growth trajectories and rebound (defined as ≥25% increase in lesion size within 6 months, usually within 3 months, of stopping therapy). Results: Thirty-patients (range, 3-23 years) were treated at the RP2D of 550 mg/m 2 twice a day: 22 low-grade glioma (LGG) and 8 high-grade glioma (HGG). PFS at 6 months (PFS6) for the entire cohort was 80% (95% CI, 67 to 96). In patients with LGG, PFS6 was higher at 86% (95% CI, 73 to 100), compared with 63% (95% CI, 37 to 100) in patients with HGG. The best responses were stable disease (13 patients) and partial responses (13 patients). Four patients experienced PD, with three patients in the HGG cohort. Responsiveness varied by lesion type, with cystic lesions showing a larger and longer-lasting decrease in tumor size than solid lesions. Of 13 patients with LGG who discontinued treatment and had follow-up imaging, 3 (23%) experienced rebound within 78-97 days. The most common grade 3 adverse event was maculopapular rash (57%). Conclusion: Vemurafenib showed efficacy in children with recurrent or progressive BRAF V600E -mutant brain tumors with acceptable toxicity. However, the rebound rate of 23% warrants further investigation.
- 25 July 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
Intracerebroventricular B7-H3-targeting chimeric antigen receptor T cells for non-pontine diffuse midline glioma and recurrent/refractory pediatric CNS tumors: A phase 1 trial
Background: High-grade central nervous system (CNS) tumors carry a poor prognosis with limited curative options if first-line therapy fails. B7-H3 is expressed in many of these tumors, and chimeric antigen receptor (CAR) T cell therapy is an emerging immunotherapeutic strategy. Methods: BrainChild-03 (NCT04185038) is a single-center, dose-escalation phase 1 study of repeated intracerebroventricular (ICV) B7-H3 CAR T cells in children and young adults with recurrent/refractory CNS tumors (Arms A and B) and diffuse intrinsic pontine glioma (Arm C). Here, we report results from Arm B, in which patients with refractory/relapsed CNS tumors or pre- or post-progression non-pontine diffuse midline glioma (DMG) received repeated ICV infusions. Primary objectives were feasibility and safety/tolerability; secondary objectives included CAR T cell detection, disease response, and survival. Results: Of 36 enrolled patients (atypical teratoid rhabdoid tumor n = 5, DMG n = 8, embryonal tumor with multilayer rosettes n = 2, ependymoma n = 4, high-grade glioma n = 6, medulloblastoma n = 8, pineoblastoma n = 3), manufacturing was successful for 35 patients, 26 of whom received therapy. Median age was 10 years (range 1-26). Dose escalation from 1 × 107 to 10 × 107 CAR T cells/dose identified this dose as the maximally tolerated dose regimen, with no dose-limiting toxicities observed. Across 181 total doses (median 7/patient), common adverse events included headache (n = 26), fever (n = 15), and nausea (n = 14). Median survival from first infusion was 11.5 months, ranging from 3.2 months (pineoblastoma, high-grade glioma) to 21.4 months (ependymoma); 2 patients achieved a partial response. Conclusions: Repeated ICV B7-H3 CAR T cell dosing is feasible and tolerable across a spectrum of pediatric CNS tumors, supporting continued investigation in future trials.
- 25 July 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
Intracerebroventricular B7-H3-targeting chimeric antigen receptor T cells for non-pontine diffuse midline glioma and recurrent/refractory pediatric CNS tumors: A phase 1 trial
Background: High-grade central nervous system (CNS) tumors carry a poor prognosis with limited curative options if first-line therapy fails. B7-H3 is expressed in many of these tumors, and chimeric antigen receptor (CAR) T cell therapy is an emerging immunotherapeutic strategy. Methods: BrainChild-03 (NCT04185038) is a single-center, dose-escalation phase 1 study of repeated intracerebroventricular (ICV) B7-H3 CAR T cells in children and young adults with recurrent/refractory CNS tumors (Arms A and B) and diffuse intrinsic pontine glioma (Arm C). Here, we report results from Arm B, in which patients with refractory/relapsed CNS tumors or pre- or post-progression non-pontine diffuse midline glioma (DMG) received repeated ICV infusions. Primary objectives were feasibility and safety/tolerability; secondary objectives included CAR T cell detection, disease response, and survival. Results: Of 36 enrolled patients (atypical teratoid rhabdoid tumor n = 5, DMG n = 8, embryonal tumor with multilayer rosettes n = 2, ependymoma n = 4, high-grade glioma n = 6, medulloblastoma n = 8, pineoblastoma n = 3), manufacturing was successful for 35 patients, 26 of whom received therapy. Median age was 10 years (range 1-26). Dose escalation from 1 × 107 to 10 × 107 CAR T cells/dose identified this dose as the maximally tolerated dose regimen, with no dose-limiting toxicities observed. Across 181 total doses (median 7/patient), common adverse events included headache (n = 26), fever (n = 15), and nausea (n = 14). Median survival from first infusion was 11.5 months, ranging from 3.2 months (pineoblastoma, high-grade glioma) to 21.4 months (ependymoma); 2 patients achieved a partial response. Conclusions: Repeated ICV B7-H3 CAR T cell dosing is feasible and tolerable across a spectrum of pediatric CNS tumors, supporting continued investigation in future trials.
- Open Access
- 11 April 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (7) , e70326
Evaluating the Utility of Paired Tumor and Germline Targeted DNA Sequencing for Pediatric Oncology Patients: A Single Institution Report
Objective: To evaluate the diagnostic yield and utility of universal paired tumor–normal multigene panel sequencing in newly diagnosed pediatric solid and central nervous system (CNS) tumor patients and to compare the detection of germline pathogenic/likely pathogenic variants (PV/LPVs) against established clinical referral criteria for cancer predisposition assessment. Methods: From May 2021 to November 2022, all patients with newly diagnosed and previously untreated CNS and non‐CNS solid tumors who had planned ongoing oncology care at Seattle Children's Hospital were offered paired tumor–normal targeted next‐generation sequencing (NGS) using the UW‐OncoPlex cancer gene panel, versions 6, 7, and 8. Known variant testing was offered to a subset of parents whose child was identified to carry a PV/LPV in a cancer susceptibility gene (CSG). Participant data was retrospectively reviewed based on the most utilized pediatric cancer predisposition screening tools to determine whether a patient met clinical criteria for referral for genetic assessment. Results: A total of 193 patients were eligible for sequencing. A number of 158/193 (82%) patients underwent paired tumor–normal sequencing. Twenty‐eight (17.7%) patients tested positive for a PV/LPV in a CSG. Ten (6.3%) patients had a P/LPV in a CSG associated with adult‐onset cancer risks. Four of 28 (14.2%) patients with a PV/LPV in a CSG would have been missed by phenotype or family history‐based referral criteria. Conclusions: Paired tumor–normal multigene panel testing of pediatric tumors remains an unbiased method of capturing patients with an underlying cancer predisposition syndrome that may otherwise go undetected with more selective screening tools.
- 11 April 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (7) , e70326
Open AccessEvaluating the Utility of Paired Tumor and Germline Targeted DNA Sequencing for Pediatric Oncology Patients: A Single Institution Report
Objective: To evaluate the diagnostic yield and utility of universal paired tumor–normal multigene panel sequencing in newly diagnosed pediatric solid and central nervous system (CNS) tumor patients and to compare the detection of germline pathogenic/likely pathogenic variants (PV/LPVs) against established clinical referral criteria for cancer predisposition assessment. Methods: From May 2021 to November 2022, all patients with newly diagnosed and previously untreated CNS and non‐CNS solid tumors who had planned ongoing oncology care at Seattle Children's Hospital were offered paired tumor–normal targeted next‐generation sequencing (NGS) using the UW‐OncoPlex cancer gene panel, versions 6, 7, and 8. Known variant testing was offered to a subset of parents whose child was identified to carry a PV/LPV in a cancer susceptibility gene (CSG). Participant data was retrospectively reviewed based on the most utilized pediatric cancer predisposition screening tools to determine whether a patient met clinical criteria for referral for genetic assessment. Results: A total of 193 patients were eligible for sequencing. A number of 158/193 (82%) patients underwent paired tumor–normal sequencing. Twenty‐eight (17.7%) patients tested positive for a PV/LPV in a CSG. Ten (6.3%) patients had a P/LPV in a CSG associated with adult‐onset cancer risks. Four of 28 (14.2%) patients with a PV/LPV in a CSG would have been missed by phenotype or family history‐based referral criteria. Conclusions: Paired tumor–normal multigene panel testing of pediatric tumors remains an unbiased method of capturing patients with an underlying cancer predisposition syndrome that may otherwise go undetected with more selective screening tools.
- 19 March 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (6) , 1594-1595
Response to “Reporting of outcomes of young children with embryonal CNS tumors after radiotherapy-avoiding strategies: Comments on ACNS0334”
Sarah E S Leary, Guolian Kang, Paul D Aridgides, Jeffrey Gossett, Claire Mazewski, Maryam Fouladi; Response to “Reporting of outcomes of young children wit
- 19 March 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (6) , 1594-1595
Response to “Reporting of outcomes of young children with embryonal CNS tumors after radiotherapy-avoiding strategies: Comments on ACNS0334”
Sarah E S Leary, Guolian Kang, Paul D Aridgides, Jeffrey Gossett, Claire Mazewski, Maryam Fouladi; Response to “Reporting of outcomes of young children wit
- Open Access
- 19 February 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 13 (4) , 807-815
A multi-institutional report of children with atypical teratoid rhabdoid tumor treated with intensive multimodal therapy
Background: Atypical teratoid rhabdoid tumor (ATRT) is a rare pediatric central nervous system tumor with little data on the efficacy of upfront treatment strategies. This study reports prognostic factors and survival of children with newly diagnosed ATRT at high-volume centers treated as per the Children’s Oncology Group trial ACNS0333. Methods: Data were collected retrospectively from 13 institutions. Included subjects were children with newly diagnosed ATRT, treated as per ACNS0333, a single-arm phase III trial of intensive chemotherapy and radiation therapy (RT). Data were analyzed to assess the prognostication of clinical variables and estimates of event-free survival (EFS) and overall survival (OS). Results: Eighty subjects were included, with a median age at diagnosis of 18 months, 70% had localized disease, and 53% underwent complete tumor resection at the time of diagnosis. Fifty patients (63%) completed all therapy phases, while 12 patients (15%) experienced progression during treatment. Fifty-three patients (66%) received post-induction consolidation with high-dose chemotherapy and stem cell rescue (HDC/SCR), and 55 (69%) received RT. The 4-year EFS and OS for the entire cohort were 49% and 53%, respectively. Patients completing all therapy phases had superior outcomes (4-year EFS: 63%; OS: 67%). Absence of disease post-induction correlated with improved outcomes (4-year EFS: 64%; OS: 70%), and patients with primary spinal cord tumors had poor outcomes despite intensive therapy. Conclusions: Children with ATRT treated as per ACNS0333 with multi-modal therapy, including HDC/SCR and RT, have improved survival compared to those treated without RT and is higher than previously reported on study.
- 19 February 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 13 (4) , 807-815
Open AccessA multi-institutional report of children with atypical teratoid rhabdoid tumor treated with intensive multimodal therapy
Background: Atypical teratoid rhabdoid tumor (ATRT) is a rare pediatric central nervous system tumor with little data on the efficacy of upfront treatment strategies. This study reports prognostic factors and survival of children with newly diagnosed ATRT at high-volume centers treated as per the Children’s Oncology Group trial ACNS0333. Methods: Data were collected retrospectively from 13 institutions. Included subjects were children with newly diagnosed ATRT, treated as per ACNS0333, a single-arm phase III trial of intensive chemotherapy and radiation therapy (RT). Data were analyzed to assess the prognostication of clinical variables and estimates of event-free survival (EFS) and overall survival (OS). Results: Eighty subjects were included, with a median age at diagnosis of 18 months, 70% had localized disease, and 53% underwent complete tumor resection at the time of diagnosis. Fifty patients (63%) completed all therapy phases, while 12 patients (15%) experienced progression during treatment. Fifty-three patients (66%) received post-induction consolidation with high-dose chemotherapy and stem cell rescue (HDC/SCR), and 55 (69%) received RT. The 4-year EFS and OS for the entire cohort were 49% and 53%, respectively. Patients completing all therapy phases had superior outcomes (4-year EFS: 63%; OS: 67%). Absence of disease post-induction correlated with improved outcomes (4-year EFS: 64%; OS: 70%), and patients with primary spinal cord tumors had poor outcomes despite intensive therapy. Conclusions: Children with ATRT treated as per ACNS0333 with multi-modal therapy, including HDC/SCR and RT, have improved survival compared to those treated without RT and is higher than previously reported on study.
- Open Access
- 1 January 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Pediatrics
- Vol. 2 (1)
Response Assessment in Pediatric Neuro-Oncology Symposium, Pediatric Society of Neuro-Oncology proceedings: Current status and future initiatives
Response Assessment in Pediatric Neuro-Oncology (RAPNO) is an international working group dedicated to developing standardized recommendations for response assessment in children with central nervous system tumors enrolled on clinical trials. This standardization facilitates easier and more reliable comparison of responses across trials. Since the first RAPNO publication in 2013, response guidelines have been issued for medulloblastoma (MB), low-grade glioma (LGG), high-grade glioma (HGG), diffuse intrinsic pontine glioma, ependymoma, and craniopharyngioma. Many of these guidelines have already been incorporated into clinical trials to evaluate their effectiveness and accuracy. RAPNO has always been predicated on the idea that these consensus recommendations will require updates over time as they are applied in practice given technological advancements, evolving treatment approaches, and growing knowledge of disease pathology. A half-day RAPNO symposium sponsored by the Society of Neuro-Oncology was held in San Diego, California, United States, on May 15, 2025. This event coincided with the 8th Biennial Pediatric Society of Neuro-Oncology meeting. The main objectives were to identify ongoing RAPNO challenges, discuss potential updates, and plan future initiatives across 3 specific groups: (1) LGG/Craniopharyngioma, (2) HGG/diffuse midline glioma (DMG)/Ependymoma, and (3) MB and other seeding tumors. This manuscript reviews the symposium proceedings and highlights key topics and challenges discussed, as well as outlining future RAPNO initiatives.
- 1 January 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Pediatrics
- Vol. 2 (1)
Open AccessResponse Assessment in Pediatric Neuro-Oncology Symposium, Pediatric Society of Neuro-Oncology proceedings: Current status and future initiatives
Response Assessment in Pediatric Neuro-Oncology (RAPNO) is an international working group dedicated to developing standardized recommendations for response assessment in children with central nervous system tumors enrolled on clinical trials. This standardization facilitates easier and more reliable comparison of responses across trials. Since the first RAPNO publication in 2013, response guidelines have been issued for medulloblastoma (MB), low-grade glioma (LGG), high-grade glioma (HGG), diffuse intrinsic pontine glioma, ependymoma, and craniopharyngioma. Many of these guidelines have already been incorporated into clinical trials to evaluate their effectiveness and accuracy. RAPNO has always been predicated on the idea that these consensus recommendations will require updates over time as they are applied in practice given technological advancements, evolving treatment approaches, and growing knowledge of disease pathology. A half-day RAPNO symposium sponsored by the Society of Neuro-Oncology was held in San Diego, California, United States, on May 15, 2025. This event coincided with the 8th Biennial Pediatric Society of Neuro-Oncology meeting. The main objectives were to identify ongoing RAPNO challenges, discuss potential updates, and plan future initiatives across 3 specific groups: (1) LGG/Craniopharyngioma, (2) HGG/diffuse midline glioma (DMG)/Ependymoma, and (3) MB and other seeding tumors. This manuscript reviews the symposium proceedings and highlights key topics and challenges discussed, as well as outlining future RAPNO initiatives.
- 19 December 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (5) , 1286-1297
Phase 3 randomized trial of postirradiation chemotherapy in patients with newly diagnosed ependymoma: A report from the Children’s Oncology Group
Background: The utility of chemotherapy for childhood ependymoma is uncertain without a prior randomized trial. Methods: ACNS0831, a multicenter phase 3 randomized study conducted through the Children’s Oncology Group (COG), included patients 1-21 years with newly diagnosed intracranial ependymoma. Patients with complete/near-total resections (GTR/NTR) or complete response (CR) to induction therapy were randomized to radiation (RT) alone or RT followed by chemotherapy (RT-CHEMO). Primary outcomes were event-free survival (EFS) and overall survival (OS). Due to anticipated noncompliance with chemotherapy, an “as treated” analysis was planned. Patients with subtotal resection (STR) were non-randomly assigned to RT-CHEMO. Grade 2 supratentorial tumors with GTR or CR to induction therapy were observed. Results: Of 449 eligible patients, 325 with GTR/NTR or CR were randomized. Five-year EFS was 63.7% (95% CI: 55.1%-71.1%) for RT only (n = 161) versus 69.2% (60.8%-76.3%) for RT-CHEMO (n = 164) (1-sided log-rank P = .299, HR = 0.866). Five-year OS was 86.9% (79.8%-91.6%) for RT only versus 88.3% (81.8%-92.6%) for RT-CHEMO (1-sided log-rank P-value = .172, HR = 0.757). The “as treated” and “as randomized” analysis results were similar. Sixty-three subjects with STR were assigned to RT-CHEMO; 5-year EFS was 33.6% (22.1%-45.5%) and OS 74.0% (60.5%-83.5%). Supratentorial grade 2 tumors with GTR or CR were observed with a 5-year EFS of 66.9% (49.0%-79.7%) and OS of 100%. Molecular classification was provided for 94% (n = 422) of all subjects. Conclusions: Primary analysis showed no benefit for maintenance chemotherapy. Further follow-up is important to assess its effect on late relapses. This is the largest cohort of molecularly classified ependymomas treated on a Phase 3 randomized trial.
- 19 December 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (5) , 1286-1297
Phase 3 randomized trial of postirradiation chemotherapy in patients with newly diagnosed ependymoma: A report from the Children’s Oncology Group
Background: The utility of chemotherapy for childhood ependymoma is uncertain without a prior randomized trial. Methods: ACNS0831, a multicenter phase 3 randomized study conducted through the Children’s Oncology Group (COG), included patients 1-21 years with newly diagnosed intracranial ependymoma. Patients with complete/near-total resections (GTR/NTR) or complete response (CR) to induction therapy were randomized to radiation (RT) alone or RT followed by chemotherapy (RT-CHEMO). Primary outcomes were event-free survival (EFS) and overall survival (OS). Due to anticipated noncompliance with chemotherapy, an “as treated” analysis was planned. Patients with subtotal resection (STR) were non-randomly assigned to RT-CHEMO. Grade 2 supratentorial tumors with GTR or CR to induction therapy were observed. Results: Of 449 eligible patients, 325 with GTR/NTR or CR were randomized. Five-year EFS was 63.7% (95% CI: 55.1%-71.1%) for RT only (n = 161) versus 69.2% (60.8%-76.3%) for RT-CHEMO (n = 164) (1-sided log-rank P = .299, HR = 0.866). Five-year OS was 86.9% (79.8%-91.6%) for RT only versus 88.3% (81.8%-92.6%) for RT-CHEMO (1-sided log-rank P-value = .172, HR = 0.757). The “as treated” and “as randomized” analysis results were similar. Sixty-three subjects with STR were assigned to RT-CHEMO; 5-year EFS was 33.6% (22.1%-45.5%) and OS 74.0% (60.5%-83.5%). Supratentorial grade 2 tumors with GTR or CR were observed with a 5-year EFS of 66.9% (49.0%-79.7%) and OS of 100%. Molecular classification was provided for 94% (n = 422) of all subjects. Conclusions: Primary analysis showed no benefit for maintenance chemotherapy. Further follow-up is important to assess its effect on late relapses. This is the largest cohort of molecularly classified ependymomas treated on a Phase 3 randomized trial.
- 29 September 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 27 (12) , 3321
Response to: Bayesian reappraisal of ACNS0332 and ACNS0334 strengthens subgroup treatment effects in high-risk pediatric group 3 medulloblastoma
- 29 September 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 27 (12) , 3321
Response to: Bayesian reappraisal of ACNS0332 and ACNS0334 strengthens subgroup treatment effects in high-risk pediatric group 3 medulloblastoma